DGAP-News

EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN SAPIENS STEERING BRAIN STIMULATION, DEVELOPER OF DEEP BRAIN STIMULATION SOLUTIONS TO MEDTRONIC - Seite 2

advanced deep brain stimulation system," said Jan Keltjens, chief executive
officer at Sapiens SBS. "We are excited to join Medtronic, and look forward
to collectively working to bring this and other novel technologies and
therapies to neuromodulation patients worldwide that could benefit from
them."
"In only about 3 years, Sapiens SBS has achieved a lot. Also, the way
founders, management, board and investors have worked together in this
company is, in my opinion, quite exceptional. Through this trade sale, in
addition to making good return for our Limited Partners, it is very
satisfying to see now the Sapiens' products integrated into the
neurostimulation franchise of the DBS market leader, as it gives this
technology the best chances of helping patients in the near future".

Sapiens was the thirteenth investment of BioDiscovery 3, a specialized life
science investment fund managed by Edmond de Rothschild Investment
Partners. Raised in 2008, the Fund has invested from 2008 to 2012 in a
portfolio of 14 companies. So far six of these companies have been sold
through private transactions and two have been listed on public financial
markets.

About Edmond de Rothschild Investment Partners

Edmond de Rothschild Investment Partners is the private equity affiliate of
the Edmond de Rothschild Group, which is specialized in asset management
and private banking (EUR 133.6bn under management, nearly 2,800 employees
spread across 31 offices, branches and subsidiaries throughout the world).
Founded in 1953, the Group has been chaired since 1997 by Baron Benjamin de
Rothschild.

Paris-based Edmond de Rothschild Investment Partners is dedicated to
minority investments into privately-owned companies. It currently has more
than EUR1 billion under management which is being invested primarily as
life sciences venture capital and growth capital.

Within Edmond de Rothschild Investment Partners, its Life Sciences Team of
eight professionals brings together over 60 years of experience in the Life
Science industry and more than 100 years of private equity and venture
capital experience. The Team has raised EUR450 million through its
Biodiscovery franchise and is currently investing BioDiscovery 4. Since
inception, BioDiscovery Funds have invested in 49 companies, of which 13
have been sold and 12 listed on public financial markets. 19 are still
active in the portfolios.

BioDiscovery Funds, including BioDiscovery 4, are venture capital funds
dedicated to professional investors. These funds are not authorized by the
Autorité des Marchés Financiers and may adopt special investment rules.

For more information : www.edrip.fr

Contacts

Edmond de Rothschild Investment Partners

Olivier Litzka

[e-mail]

Tel: [phone]



---------------------------------------------------------------------

26.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


283934 26.08.2014